Posted by Michael Wonder on 28 Dec 2023
Formycon announces EMA acceptance of the MAA for FYB203, a biosimilar candidate to Eylea (aflibercept)
27 December 2023 - Formycon and its license partner Klinge Biopharma announce that the EMA has accepted the marketing authorisation application for FYB203, a biosimilar candidate to Eylea (aflibercept), for review.
Aflibercept is used in the treatment of neovascular age-related macular degeneration and other severe retinal diseases.
